PolTREG Gets Patent Approval in China for Treg Therapy
PolTREG S.A., a clinical-stage biotechnology firm dedicated to innovative cellular therapies, has just received significant news from China. The National Intellectual Property Administration (CNIPA) has granted a patent that strengthens the company’s work in treating multiple sclerosis (MS) with its PTG-007 Treg cell therapy. This announcement marks an important milestone for PolTREG as it gears up to broaden its clinical studies.
Importance of the Patent
The newly approved patent covers the intrathecal delivery method of PolTREG's PTG-007 therapy, allowing for targeted treatment that can effectively cross the blood-brain barrier. This method is crucial for conditions like MS, where the neurological tissue needs direct intervention. Earlier Phase I trials have indicated that this approach yields significantly better results compared to traditional systemic treatments.
Upcoming Clinical Trials
PolTREG plans to kick off two Phase 2 trials focused on relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) in the next few months. These studies aim to validate the encouraging results seen with PTG-007 and will include a substantial number of patients across both MS types. The first study is expected to begin in the fourth quarter of 2024.
Findings from Previous Studies
Early data from a Phase 1/2a safety study indicated that patients who received PTG-007 via intrathecal administration showed remarkable outcomes, such as minimal brain lesion activity. This stands in contrast to those who received the therapy through intravenous means. As larger trials are planned to reinforce these findings, excitement is building around the ongoing potential of Treg cell therapies.
PolTREG's Market Position
As a frontrunner in Treg therapies for autoimmune diseases, PolTREG is distinguished by its extensive development pipeline, which includes both engineered and polyclonal Treg treatments. Its leading candidate, PTG-007, has achieved significant milestones in the clinical field, especially in addressing type 1 diabetes. PolTREG’s success in developing a comprehensive therapeutic regimen underscores its commitment to effectively manage various autoimmune conditions.
Facilities and Manufacturing Capabilities
PolTREG operates a cutting-edge GMP-certified facility dedicated to the production of its Treg therapies. This allows the company to uphold high quality and safety standards in its products. Additionally, with over 2,100 square meters of laboratory space and the capability to ship treatments across Europe within 24 hours, PolTREG is well-equipped to support its clinical research and therapeutic goals.
Contact Information
For more details about PolTREG and its innovative Treg therapies, feel free to reach out to:
PolTREG S.A.
Prof Piotr Trzonkowski
Chief Executive Officer
ir@poltreg.com
+48 512 532 401
Investor Relations
Frank Hoerning-Andersen
Cohesion Bureau
+45 25 66 86 02
frank.hoerning@cohesionbureau.com
Media Relations
Douwe Miedema
Cohesion Bureau
+352 621 562 764
douwe.miedema@cohesionbureau.com
Frequently Asked Questions
What is PTG-007?
PTG-007 is PolTREG's leading candidate for Treg cell therapy, aimed at targeting autoimmune diseases such as type 1 diabetes and multiple sclerosis.
Why does intrathecal administration matter?
This method allows for precise delivery of therapies through the blood-brain barrier, improving effectiveness in treating conditions like multiple sclerosis.
What outcomes are expected from the upcoming Phase 2 trials?
The Phase 2 trials are designed to confirm earlier study results that showed decreased lesion development and fewer serious side effects in MS patients.
How does PolTREG's GMP facility aid their therapies?
The GMP facility guarantees the high-quality manufacturing of Treg therapies, which is essential for the safety and efficacy of their treatments.
Who can I ask for more details about PolTREG?
For any inquiries, you can contact Prof Piotr Trzonkowski, the CEO of PolTREG, to get in-depth information about the company's operations.
